Soft tissue healing is mainly defined as the overall replacement of the destroyed tissue by living tissue in the body. This process primarily consists of two components – regeneration and repair process. In the case of the regeneration component, specialized tissue is mainly replaced by the proliferation of the surrounding undamaged specialized cells, whereas, in the repair component, the lost tissue is replaced by the granulation tissue that matures into scar tissue in the future. The cellular reaction after injury highly depends on the tissue type and the total extent of the wound.
In other words, the soft tissue repair process replaces the damaged or the injured tissues with healthy ones (Fibroplasia and Angiogenesis) with the help of the epithelialization process. Moreover, methods like Electrotherapy, Allografts, and xenografts which have a poor success rate, are now the most common therapeutic alternatives. As a result, superior and technologically sophisticated alternatives, like less invasive treatments and quick-healing solutions, are highly essential. Muscles, ligaments, and tendons containing the CNS and the non-CNS tissues often suffer from soft tissue injuries, thereby causing contraction, discomfort, and inflammation. As per Johns Hopkins University’s study, about 30 million teens and children in the United States participate in organized sports. Also, every year, around 3.5 million injuries occur, thereby enhancing the overall growth rate of the Soft Tissue Repair market.
The total valuation of the Global Soft Tissue repair Market was around USD 11.82 billion in 2020, & it is expected to grow at a decent CAGR of around 6.81% from 2020 to 2030. As a result of this, the soft tissue market size is expected to reach around USD 22.84 billion by the end of the year 2030.
Recent Developments regarding the Global Soft tissue repair Market
- In the month of December 2020, ACell was successfully purchased for around $300 million by Integra Lifesciences. The deal was done to boost the tissue regeneration capabilities of Integra Lifescienceswhile also complementing the company’s current portfolio of various tissue technologies.
- In the month of October 2020, the O-GENESIS Graft Delivery System and AlloQuent Structural Allograft Q-Pack, which is a ready-to-use cervical and lumbar spacers, especially for the allograft surgeries, were introduced by Orthofix Medical Inc. in the United States.
- In the month of April 2020, The ClearGuard LE Endoscopic Soft Tissue Release System, which the orthopaedic and podiatric specialists primarily use to treat a wide range of foot problems, was introduced in the United States by In2Bones, a US-based distributor, designer, and manufacturer of medical devices for the treatment of various disorders and injuries. Also, for high-volume lower extremity, various soft tissue procedures such as gastrocnemius, plantar fascia, tarsal tunnel, and Morton’s neuroma, the ClearGuard LE Endoscopic Soft Tissue Release Technology delivers the orthopaedic and podiatric experts with an easy-to-use, reproducible, and cost-effective system.
- In the month of February 2020, Peri-Strips Dry with Veritas Collagen Matrix with Secure Grip gained the FDA 510(k) approval from Baxter. The product is a total reinforcing agent that is used to prevent bleeding during bariatric and other surgical processes.